Long-Term Metabolic Effects and Recurrence of Weight Gain a Decade Post Roux-en-Y Gastric Bypass: Findings from a Longitudinal Cohort Analysis - Scorecard - MDSpire
Advertisement
Long-Term Metabolic Effects and Recurrence of Weight Gain a Decade Post Roux-en-Y Gastric Bypass: Findings from a Longitudinal Cohort Analysis
Clinical Scorecard: Long-Term Metabolic Effects and Recurrence of Weight Gain a Decade Post Roux-en-Y Gastric Bypass: Findings from a Longitudinal Cohort Analysis
At a Glance
Category
Detail
Condition
Obesity with long-term weight management post Roux-en-Y gastric bypass (RYGB)
Key Mechanisms
RYGB induces sustained weight loss and metabolic improvements; however, recurrent weight gain (RWG) may occur long-term affecting metabolic outcomes
Target Population
Patients undergoing Roux-en-Y gastric bypass surgery
Care Setting
Tertiary referral hospital metabolic bariatric surgery outpatient clinics
Key Highlights
RYGB promotes sustained weight loss and improvements in associated medical problems and quality of life.
Significant recurrent weight gain (>30% from nadir) occurs in a substantial proportion of patients by 10 years post-surgery.
Despite RWG, meaningful long-term metabolic benefits and reduced cardiovascular risk may persist up to 10 years after RYGB.
Guideline-Based Recommendations
Diagnosis
Define diabetes mellitus type 2 by fasting plasma glucose ≥7 mmol/L, HbA1c ≥6.5%, or use of antidiabetic medication.
Define hypertension as systolic blood pressure ≥140/90 mmHg or use of antihypertensive medication.
Define dyslipidemia by LDL ≥3.0 mmol/L, HDL <1.0 mmol/L (men) or <1.3 mmol/L (women), triglycerides >1.7 mmol/L, total cholesterol/HDL ratio >5, or use of lipid-lowering medication.
Management
Perform laparoscopic RYGB with a 25 ml gastric pouch, 150 cm alimentary limb, and 50 cm biliopancreatic limb.
Prescribe oral Ursodeoxycholic acid 250 mg twice daily for 6 months postoperatively to reduce gallstone risk.
Provide lifelong supplementation with oral multivitamins, iron, vitamin D, calcium, and intramuscular vitamin B12 injections.
Monitoring & Follow-up
Schedule follow-up consultations at 6-8 weeks, 6 months, 1, 2, 5, and 10 years post-RYGB.
Measure weight, height, blood pressure, and fasting blood samples at each follow-up.
Adjust supplementation based on laboratory results and clinical assessment during follow-up.
Risks
Monitor for recurrent weight gain defined as >30% increase from nadir weight after surgery.
Recognize potential relapse of associated medical problems such as diabetes, hypertension, and dyslipidemia after initial remission.
Be aware of complications during long-term follow-up, though specific complications were not detailed in the excerpt.
Patient & Prescribing Data
Patients undergoing primary laparoscopic Roux-en-Y gastric bypass for obesity
Postoperative prescriptions include Ursodeoxycholic acid for gallstone prevention and lifelong vitamin and mineral supplementation to prevent deficiencies.
Clinical Best Practices
Use standardized definitions for weight loss and recurrent weight gain to monitor patient progress.
Employ validated quality of life instruments such as SF-36v2 to assess patient-reported outcomes at long-term follow-up.
Ensure multidisciplinary follow-up with consistent measurement of metabolic parameters and adjustment of supplementation.
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
